Company Overview and News

0
Alacer Gold Announces Release Date for Second Quarter 2018 Operational and Financial Results Conference Call

2018-07-16 globenewswire
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) and (ASX:AQG) plans to release its second quarter 2018 operating results, financial statements and the related management’s discussion and analysis before the TSX market opens on Tuesday, July 31, 2018 (North America).
AQG ALIAF ASR ALACF

0
Alacer Gold Announces an Increase to 2018 Oxide Plant Production Guidance at Reduced All-In Sustaining Costs and Reaffirms Sulfide Plant Production Guidance & Schedule

2018-07-09 globenewswire
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Company”) (TSX:ASR) (ASX:AQG) announces an increase to its 2018 oxide plant production guidance to 110,000 – 130,000 ounces at reduced oxides All-in Sustaining Costs of $650 – $700 per ounce1. Production guidance from the sulfide plant remains unchanged at 50,000 – 100,000 ounces, with the construction of the plant remaining on schedule and under budget.
AQG ALIAF ASR ALACF

1
Blackham Resources bolsters Board with appointment of experienced mining engineer

2018-06-22 proactiveinvestors.com.au
Blackham Resources Ltd (ASX:BLK) has strengthened its Board with the appointment of experienced mining engineer Tony James as a non-executive director.
AQG ALIAF CRNRF BKHRF ASR DRM BLK ALACF CRB

1
Alacer Gold Announces Results of Annual and Special Meeting of Shareholders

2018-06-08 globenewswire
TORONTO, June 08, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) (ASX:AQG) is pleased to announce the results of its 2018 Annual and Special Meeting of Shareholders (the “Meeting”) held on June 7, 2018 in Denver, Colorado.
AQG ALIAF ASR ALACF

19
CANADA STOCKS-Energy shares drag TSX lower as oil prices slip

2018-06-06 reuters
June 6 (Reuters) - Canada’s main stock index edged lower on Wednesday, weighed down by energy stocks that slipped due to lower oil prices.
ALIAF AQG DRG.UN IVPAF TWMJF ACB ASR WEED ACBFF IVN ALACF CGC

1
Alacer Gold - 2 Hidden Factors Driving The Company's Value Up

2018-05-22 seekingalpha
In Q3 2018 Alacer Gold will start producing gold from the sulfide zone of the Copler mine.
ALIAF AQG ASR ALACF

1
Alacer Gold Corp's (ALIAF) CEO Rodney Antal on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Welcome to the Alacer Gold First Quarter 2018 Operating and Financial Results Conference call. As a reminder all participants are in listen-only mode and the conference is being recorded. After the presentation there will be an opportunity to ask questions. [Operator Instructions].
ALIAF AQG ASR ALACF

15
Is Palladium Losing Strength against Gold?

2018-05-01 marketrealist
Palladium has been the weakest among the four precious metals on a YTD (year-to-date) basis. Palladium has seen a YTD fall of 8.7%. The fall in car demand in China may be the reason behind the massive palladium price crash.
ALIAF AQG ELD ASR ALACF EGO

1
Alacer Gold Corp. 2018 Q1 - Results - Earnings Call Slides

2018-05-01 seekingalpha
The following slide deck was published by Alacer Gold Corp. in conjunction with their 2018 Q1 earnings call.
ALIAF AQG ASR ALACF

22
Gold and Dollar Moved Together on Wednesday

2018-04-20 marketrealist
A crucial factor that continues to affect gold is the US dollar. On Wednesday, gold and the US dollar rose 0.15% and 0.12%, respectively. However, these two move in the opposite direction most of the time. On a YTD (year-to-date) basis, gold has risen 3.4%, while the dollar has lost 2.7%.
ALIAF AQG ELD KGC ASR K HL ALACF HL.PRB EGO

23
How Precious Metals and Miners Moving in April?

2018-04-19 marketrealist
Precious metals had another up day as gold futures for April expiration rose 0.48% on Friday, April 13, closing at $1,344.80 per ounce. Silver rose 1.1%, ending the day at $16.60 per ounce.
ALIAF AQG NGD ASR NGDAF ALACF NGD

3
US Inflation Rises: How Will It Impact Gold Prices?

2018-04-16 marketrealist
According to the US Bureau of Labor Statistics, the US consumer price index (or CPI) rose 2.4% year-over-year (or YoY) in March 2018. This is its fastest pace in the last 12 months. The core CPI, which excludes volatile food and energy components, rose 0.2% over the previous month and 2.1% YoY in March. This was the biggest gain in core prices since February 2017.
ALIAF AQG GFI.WI ASR ALACF GFI GFIOF

29
Are US-China Jitters Affecting Precious Metals?

2018-04-10 marketrealist
Gold, silver, platinum, and palladium increased 0.33%, 1%, 2.4%, and 4.2%, respectively, on Monday. Gold futures for April expiration were trading at $1,336.3 an ounce on Monday, April 9. The volatility in gold was at 10.4%, while its RSI level was at 59.7. Silver futures for April expiration closed at $16.5 per ounce. Silver’s volatility was at 17.4% and its RSI level was at 58. Platinum and palladium were at $933.
ALIAF AQG O87 KGC ELD ASR K ALACF GLD EGO

1
Alacer Gold Announces Release Date for First Quarter 2018 Operational and Financial Results Conference Call

2018-04-10 globenewswire
TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) (ASX:AQG) plans to release its first quarter 2018 operating results, financial statements and the related management’s discussion and analysis before the Toronto Stock Exchange opens on Tuesday, May 1, 2018 (North America).
AQG ALIAF ASR ALACF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...